An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection
Authors:
- 1 September 2017
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 50, 87-94
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest ChinaVirology Journal, 2017
- Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapyClinical Microbiology and Infection, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionNew England Journal of Medicine, 2015
- Novel therapies for hepatitis C — one pill fits all?Nature Reviews Drug Discovery, 2013
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Micromanaging Hepatitis C VirusNew England Journal of Medicine, 2013
- Chronic Hepatitis C InfectionNew England Journal of Medicine, 2011
- The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune DisordersInflammation & Allergy - Drug Targets, 2009
- The inhibitory cytokine IL-35 contributes to regulatory T-cell functionNature, 2007
- IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cellsEuropean Journal of Immunology, 2007